Expansion of PCR-Test Portfolio Roche Acquires Long-Term Partner TIB Molbiol
Healthcare company Roche has completed its share purchase agreement to acquire 100 percent of the outstanding shares of TIB Molbiol Group. The acquisition enables the group to further expand the portfolio of CE-IVD assays and research use assays.
Basel/Switzerland — Following the takeover by Roche, TIB Molbiol will continue to operate as a subsidiary within the Diagnostics division. The companies want to build on their capabilities for the rapid development of assays for emerging pathogens and potential health threats, such as infectious diseases.
With over 45 CE-IVD assays and more than a 100 research-use-only assays joining the Roche family, the companies announced that they want to jointly accelerate access for patients around the world to even more clinically important diagnostic tests. TIB Molbiol is further expanding Roche’s molecular diagnostics solutions, especially for the flexible open platforms Light Cycler PCR and Magna Pure sample preparation systems.
The two companies have collaborated for more than 20 years to rapidly address critical healthcare needs including biological threats, such as Sars, anthrax, avian influenza virus H5N1, Mers, the novel influenza virus H1N1 swine, Ebola virus, Zika virus and most recently, Sars-CoV-2 virus and its variants. For example, in 2001 with anthrax and 2003 with Sars-CoV1, TIB Molbiol demonstrated their ability to develop PCR assays for the detection of new pathogens within days.